How Much Does CAR-T Therapy Cost, and Why Is It So Expensive?

The list prices of FDA-approved CAR-T cell therapies for blood cancers now range from roughly $373,000 to over $555,000 per infusion, and that figure covers only the manufactured cell product — not the hospitalization, ICU monitoring, and management of side effects like cytokine release syndrome that can push the real cost of a single treatment episode past $1 million. This piece lays out sourced list prices for the six major approved products, explains the manufacturing and logistical reasons CAR-T costs what it does, and summarizes what independent cost-effectiveness reviews and real-world claims data say about whether that price is justified.

What CAR-T Therapy Actually Costs: The List Prices

As of 2025, wholesale acquisition costs (WAC) for the approved autologous CAR-T products cluster between roughly $460,000 and $595,000, according to pricing data compiled by the Health Management Policy Institute (HMPI): tisagenlecleucel (Kymriah, Novartis) at $593,533; lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) at $531,350; idecabtagene vicleucel (Abecma, Bristol Myers Squibb/2seventy bio) at $528,312; ciltacabtagene autoleucel (Carvykti, Legend Biotech/Janssen) at $555,310; axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) at $503,580; and brexucabtagene autoleucel (Tecartus, Kite Pharma/Gilead) at $462,000. These figures have risen substantially from launch: Kymriah debuted at $475,000 in 2017, Yescarta and Tecartus at $373,000, Breyanzi at $410,300 (confirmed independently by pharmaphorum's coverage of the 2021 FDA approval), Abecma at $419,500, and Carvykti at $465,000. These are drug-product prices only; they exclude the leukapheresis (cell collection) procedure, lymphodepleting chemotherapy, the inpatient stay for infusion and monitoring, and treatment of any complications.

Why Autologous Manufacturing Drives the Price

Unlike a conventional small-molecule drug that is synthesized in bulk and shipped to any pharmacy, each dose of currently approved CAR-T therapy is manufactured from that specific patient's own T cells. A patient's blood is collected via apheresis, shipped to a specialized manufacturing facility, genetically engineered — typically using a viral vector to insert the chimeric antigen receptor gene — expanded to hundreds of millions of cells over roughly two to four weeks, quality-tested, frozen, and shipped back to the treatment center for infusion. MIT Technology Review describes this as a "high-tech and laborious process" and notes that viral vectors are "one of the most expensive line items in the manufacturing process," expensive enough that some manufacturers have moved to producing their own vectors in-house to control costs. Consumer health outlet Medical News Today, citing 2024 research, reported that producing a single dose requires more than 200 hours of skilled labor and that manufacturing labor alone accounts for roughly 48% of total therapy cost. Because the process cannot be batch-produced or scaled the way a conventional biologic can, and because each product currently serves a comparatively small population of eligible relapsed/refractory blood cancer patients, the fixed costs of R&D, clinical trials, specialized manufacturing infrastructure, and cold-chain logistics are spread across far fewer doses than a typical blockbuster drug.

The Hidden Cost: What Happens After the List Price

The list price is the floor, not the ceiling, of what CAR-T actually costs the healthcare system. A real-world claims analysis by Prime Therapeutics, following 74 commercially insured patients with B-cell lymphoma over 2.5 years, found that initial treatment-period costs ranged from $350,000 to over $2 million, averaged more than $700,000, and that the drug itself accounted for about 74% of that initial cost. Critically, the same analysis found that 12% of patients who experienced post-treatment complications had total cost of care exceeding $1 million. Separately, coverage in AJMC of hospital cost data found that hospitalization is "the most significant driver of cost... particularly for patients who experience toxicities," with median hospitalization costs exceeding $300,000 (approaching $400,000 in pediatric patients), and that cytokine release syndrome was the primary reason for ICU admission in 41% of cases studied. Total episode-of-care costs for patients with severe (grade 3 or higher) CRS were estimated to exceed $500,000, and AJMC reported that the American Society for Transplantation and Cellular Therapy has recommended hospitals bill $2 million to $2.5 million per case to avoid financial losses once the full cost of toxicity management is factored in.

Is the Price Justified? What Cost-Effectiveness Analyses Show

The Institute for Clinical and Economic Review (ICER), an independent nonprofit that evaluates drug value, concluded in its 2018 report that the initial launch prices of Kymriah and Yescarta were broadly aligned with their clinical benefit: axicabtagene ciloleucel's incremental cost per quality-adjusted life-year (QALY) versus chemotherapy came in around $136,000, and tisagenlecleucel's around $46,000 versus a comparator regimen for pediatric leukemia — both within or below commonly cited value thresholds of $50,000–$150,000 per QALY. However, ICER separately flagged an affordability problem distinct from value-for-money: at axicabtagene ciloleucel's price, only about 38% of eligible patients could be treated before exceeding ICER's own $915 million annual budget-impact threshold, underscoring that a therapy can be "worth it" per patient while still being unaffordable at a population level.

Insurance Coverage and Financial Assistance

Commercial insurance, Medicare, and Medicaid generally cover CAR-T therapy when it is used for an FDA-approved indication and deemed medically necessary, though prior authorization and site-of-care requirements are common. Medical News Today reported that despite the six-figure list price, cited 2024 research found a median patient copayment of just $510 for insured patients — reflecting how much of the cost is absorbed by insurers and specialty pharmacy benefit structures rather than paid directly by patients. Manufacturers also run copay assistance programs for eligible commercially insured patients (Bristol Myers Squibb offers one for Breyanzi), and nonprofit organizations provide grants to offset non-medical costs like travel and lodging, since patients often must relocate temporarily near a certified treatment center for the multi-week manufacturing and recovery period.

Bottom Line

CAR-T list prices in the $373,000–$595,000 range reflect a genuinely different manufacturing model than conventional pharmaceuticals — patient-specific cell collection, viral-vector engineering, weeks-long expansion, and cold-chain logistics for a comparatively small eligible patient population — and independent cost-effectiveness analysis from ICER has found the initial launch prices roughly proportionate to measured clinical benefit. But the list price understates the real cost of care: real-world claims data show total treatment episodes commonly exceeding $700,000 and sometimes $1–2 million once hospitalization and management of cytokine release syndrome or other toxicities are included. Anyone evaluating CAR-T therapy financially should ask their treatment center specifically about the total anticipated episode-of-care cost (not just the drug price), their insurer's prior-authorization and site-of-care requirements, and what manufacturer or nonprofit financial assistance programs they may qualify for.